2-[2-(tetrahydropyran-2-yloxy)ethoxy]phenylboronic acid | 791814-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-[2-(tetrahydropyran-2-yloxy)ethoxy]phenylboronic acid
• 英文别名: 2-[2-(Tetrahydropyran-2-yloxy)ethyl]phenylboronic acid；[2-[2-(oxan-2-yloxy)ethyl]phenyl]boronic acid
• CAS: 791814-38-5
• 化学式: C₁₃H₁₉BO₄
• 分子量: 250.102
• InChiKey: ZIGIVECDHOZKNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.45
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[2-(tetrahydropyran-2-yloxy)ethoxy]phenylboronic acid 在 palladium on activated charcoal palladium diacetate 、 sodium hydroxide 、 dimethyl sulfide borane 、 氢气 、 碳酸氢钠 、 四已基碘化铵 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 20.0 ℃ 、206.84 kPa 条件下， 反应 84.5h， 生成 17,19-Dioxa-10-azatetracyclo[12.7.0.02,7.016,20]henicosa-1(21),2,4,6,14,16(20)-hexaene
  参考文献：
  名称：

  Synthesis of the Enantiomers of Hexahydrodibenz[d,f]azecines

  摘要：

  Suzuki coupling procedures were used to make appropriate 2-(3-aminopropyl)- 2'-(2-mesyloxy)ethyl disubstituted biphenyl derivatives 19 and 20 from which the racemic hexahydrodibenz[d,f]azecines 3 and 4 were produced following intramolecular mesyloxy displacement in dilute solution. The enantiomers of the former azecine were prepared by use of an analogue of the biphenyl aminomesylate 19 having a chiral auxiliary bound to the amino group during the closure of the 10-membered ring. Absolute configurations were assigned by X-ray diffraction analysis of compound 28.

  DOI：

  10.1021/jo049157q
• 作为产物：
  描述：

  2-[2-(2-bromophenyl)ethoxy]tetrahydropyran 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.0h， 以56%的产率得到2-[2-(tetrahydropyran-2-yloxy)ethoxy]phenylboronic acid
  参考文献：
  名称：

  发现构象受限的四环化合物作为有效的丙型肝炎病毒 NS5B RNA 聚合酶抑制剂。

  摘要：

  我们报告了一系列新的丙型肝炎病毒 NS5B RNA 聚合酶抑制剂，其中包含构象受限的四环支架。SAR 研究导致鉴定 6,7-二氢-5H-苯并[5,6][1,4]二氮杂[7,1-a]吲哚（19 和 20）具有高生化和细胞效力。当在人血清白蛋白存在下进行复制子测定时，这些化合物在细胞效力方面表现出非常小的变化。

  DOI：

  10.1021/jm0610245

文献信息

• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。
• Synthesis of the Enantiomers of Hexahydrodibenz[<i>d,f</i>]azecines
  作者：Richard H. Furneaux、Graeme J. Gainsford、Jennifer M. Mason

  DOI：10.1021/jo049157q

  日期：2004.10.1

  Suzuki coupling procedures were used to make appropriate 2-(3-aminopropyl)- 2'-(2-mesyloxy)ethyl disubstituted biphenyl derivatives 19 and 20 from which the racemic hexahydrodibenz[d,f]azecines 3 and 4 were produced following intramolecular mesyloxy displacement in dilute solution. The enantiomers of the former azecine were prepared by use of an analogue of the biphenyl aminomesylate 19 having a chiral auxiliary bound to the amino group during the closure of the 10-membered ring. Absolute configurations were assigned by X-ray diffraction analysis of compound 28.
• Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors
  作者：Kazutaka Ikegashira、Takahiro Oka、Shintaro Hirashima、Satoru Noji、Hiroshi Yamanaka、Yoshinori Hara、Tsuyoshi Adachi、Jun-Ichiro Tsuruha、Satoki Doi、Yasunori Hase、Toru Noguchi、Izuru Ando、Naoki Ogura、Satoru Ikeda、Hiromasa Hashimoto

  DOI：10.1021/jm0610245

  日期：2006.11.30

  We report a new series of hepatitis C virus NS5B RNA polymerase inhibitors containing a conformationally constrained tetracyclic scaffold. SAR studies led to the identification of 6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indoles (19 and 20) bearing a basic pendent group with high biochemical and cellular potencies. These compounds displayed a very small shift in cellular potency when the replicon

  我们报告了一系列新的丙型肝炎病毒 NS5B RNA 聚合酶抑制剂，其中包含构象受限的四环支架。SAR 研究导致鉴定 6,7-二氢-5H-苯并[5,6][1,4]二氮杂[7,1-a]吲哚（19 和 20）具有高生化和细胞效力。当在人血清白蛋白存在下进行复制子测定时，这些化合物在细胞效力方面表现出非常小的变化。